Fidelity Investments
PMCB icon

Fidelity Investments’s PharmaCyte Biotech PMCB Stock Holding History

Fidelity Investments’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-6
Closed -$8 – 5456
2025
Q1 		$8 Buy
+6
New +$10 ﹤0.01% 5254
2023
Q3 		– Sell
-1
Closed -$3 – 5468
2023
Q2 		$3 Buy
+1
New +$3 ﹤0.01% 5329
2021
Q4 		– Sell
-500
Closed -$2K – 4803
2021
Q3 		$2K Buy
+500
New +$1.76K ﹤0.01% 4035

Other funds holding PMCB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

Fidelity Investments's PMCB Position: Q2 2025 in Review

Fidelity Investments sold out of PharmaCyte Biotech (PMCB) in Q2 2025, closing a stake of 6 shares — an estimated $8 sold.

Fidelity Investments first reported a position in PMCB in Q3 2021 and held it in 3 quarters. The position peaked at $2K in Q3 2021. 23 funds tracked by Wall St. Rank hold PMCB as of Q2 2025.

  • Fidelity Investments reported no remaining PharmaCyte Biotech position as of Q2 2025 after selling out during the quarter.
  • Fidelity Investments sold 6 PharmaCyte Biotech shares in Q2 2025, an estimated $8.
  • Fidelity Investments first reported a position in PharmaCyte Biotech in Q3 2021 and held it in 3 quarters.
  • Fidelity Investments's PharmaCyte Biotech position peaked at $2K in Q3 2021.
  • 23 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q2 2025.

Based on Fidelity Investments's 13F filing for Q2 2025, filed 14 Aug 2025.